scholarly journals Prognostic Significance of the L3 Skeletal Muscle Index and Advanced Lung Cancer Inflammation Index in Elderly Patients with Esophageal Cancer

2021 ◽  
Vol Volume 13 ◽  
pp. 3133-3143
Author(s):  
Xiang Tan ◽  
Huajian Peng ◽  
Peixin Gu ◽  
Mingwu Chen ◽  
Yongyong Wang
2019 ◽  
Vol 26 (11) ◽  
pp. 3727-3735 ◽  
Author(s):  
Keita Takahashi ◽  
Masayuki Watanabe ◽  
Ryotaro Kozuki ◽  
Tasuku Toihata ◽  
Akihiko Okamura ◽  
...  

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21624-e21624
Author(s):  
Konstantinos N. Syrigos ◽  
Stavroula Patsilinakou ◽  
Dimitra Grapsa ◽  
Evangelia Chrysanthopoulou ◽  
Ioannis Gkiozos ◽  
...  

e21624 Background: As shown in recent studies, inflammation plays a key role in lung cancer (LC) pathogenesis and evolution, while the potential prognostic and predictive value of various inflammation markers in different disease stages is being extensively studied. We herein aimed to further evaluate the potential prognostic value of a new inflammation marker (ALI, Advanced Lung Cancer Inflammation Index = BMI x Alb / NLR), which combines previous markers of systematic inflammation with markers of nutrition or cachexia at the time of LC diagnosis. Methods: The medical records of 67 patients, diagnosed with LC in Sismanoglio Athens General hospital, within a two-year period (January 2016-January 2017) were retrospectively studied. Demographic, clinicopathological and laboratory features of patients, including pre-treatment ALI, were recorded and correlated with prognosis (overall survival, OS). Results: A total of 67 patients were included with a mean age of 60 (± 8) years. The majority of cases were men (39/67,58.2 %), with positive smoking history (62/67, 92.5%), performance status (PS) 1-2 (43/67, 64.2%) and disease stage IV (54/67, 80.6%). Adenocarcinoma was the commonest histological type observed (19/67, 28.5%). Values of ALI ranged from 7.8 to 37.2 (mean: 21±6). The cut-off point of ALI was 19 (based on ROC curve analysis) and patients were divided into two groups: those with ALI < 19 and those with ALI ≥ 19. In univariate analysis, PS and the presence of metastatic disease, as well as ALI values < 19, were all correlated with reduced survival (p = 0.002, p = 0.028 and p = 0.018, respectively). In multivariate analysis, PS was the only parameter that retained its statistically significant correlation with an adverse prognosis (p = 0.048), although its prognostic significance was increased when combined with ALI. Conclusions: Although failing to confirm an independent prognostic value for ALI, the results of our study suggest that combination of ALI with standard prognostic predictors such as PS may improve prediction of patients’ survival. Additional prospective studies are warranted to validate the prognostic significance of this promising biomarker and expand its use in routine practice.


2021 ◽  
Vol 11 (11) ◽  
pp. 100-107
Author(s):  
V. Kechedzhyiev

Introduction. Today the relevance of sarcopenia is increasing in various types of malignant neoplasms.This syndrome is most common in patients with advanced forms of cancer and can adversely affect survival, treatment outcomes, and functional status. The prevalence of sarcopenia in patients with lung cancer is higher than in other types of malignant tumors. To understand the relationship between sarcopenia and quality of life is especially important for patients with advanced cancer. Aim. To assess the relationship between skeletal muscle index (SMI) and quality of life in sarcopenia in patients with advanced lung cancer. Materials and methods. A prospective analysis was carried out of 28 patients with advanced lung cancer who have applied to the “ONCOLIFE” Medical Center since the beginning of 2021. All patients had sarcopenia on CT scan. Skeletal muscle cross-sectional area analyzed using software ImageJ (National Institutes of Health, Bethesda, MD, USA). To determine the quality of life in sarcopenia a questionnaire SarQoL was used. Pearson's correlation analysis was used to assess the correlation between quality of life and SMI. Results. Pearson's correlation analysis showed a statistically significant positive correlation between quality of life and SMI (r = 0,451, р = 0,016, N=28). Body mass index (BMI) positively correlated with quality of life (r = 0,398, р = 0,036, N=28), and age negatively correlated with SMI (r = -0,391, р = 0,040, N=28). There was no statistically significant correlation between indicators such as BMI and SMI, as well as age and quality of life. Conclusions. Quality of life in sarcopenia statistically significantly correlates with SMI in patients with metastatic lung cancer. Early diagnosis of sarcopenia is essential for timely prescription of treatment aimed at maintaining and better muscle mass, which can improve cancer patients quality of life.


PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0164056 ◽  
Author(s):  
Eun Young Kim ◽  
Nambeom Kim ◽  
Young Saing Kim ◽  
Ja-Young Seo ◽  
Inkeun Park ◽  
...  

2018 ◽  
Vol 31 (Supplement_1) ◽  
pp. 17-17
Author(s):  
Tommi Järvinen ◽  
Ilkka Ilonen ◽  
Jari Räsänen

Abstract Background Advanced esophageal cancer often causes malignant obstruction, which is widely treated with palliative insertion of a self-expandable metallic stent (SEMS). The purpose of this study was to assess, in patients who had received SEMS for palliation of malignant obstruction caused by advanced esophageal cancer, the prognostic significance of loss of muscle mass during follow up. Methods 118 patients were included. 58 (49,2%) patients had squamous cell carcinoma, 52 (44,1%) adenocarcinoma and 8 (6,7%) other histology. Two sets of abdominal CT scans of EC patients who had a stent inserted for palliation of malignant obstruction between 2005 and 2013 were analyzed (N = 118). First scan was taken at stent insertion. Median time difference between scans was 92 days. The cross-sectional total muscle area (TMA) at the level of L3 was assessed and skeletal muscle index (SMI) was calculated by dividing the TMA with the square of the patients height in cm. Follow up lasted until death for all of the 118 patients. Results Median overall survival (OS) was 188 days (IQR: 124–255 days). Median amount of weight loss during follow up was 10 kg's (IQR: 8 -16.5 kg's). Median percentual loss of SMI was 11.6% (IQR: 1.1–19.5%). Loss of more than the median amount of %SMI correlated with worse OS (187 vs. 242 days, P = 0.018), as seen in Figure 1. Conclusion In the setting of palliatively SEMS-treated esophageal cancer, the amount of skeletal muscle lost during follow up correlates with worse prognosis. Disclosure All authors have declared no conflicts of interest.


2019 ◽  
Vol 2019 ◽  
pp. 1-9
Author(s):  
Yi Zhang ◽  
Bo Chen

Background. The advanced lung cancer inflammation index (ALI) has been related to tumor survival in lung cancer (LC) patients. However, these findings regarding the prognostic relevance of ALI in LC were inconsistent. Our study is aimed at characterizing the prognostic significance of low pretreatment ALI in LC cases. Methods. Relevant published studies were systematically searched in several online databases. The combined hazard ratios (HRs) were applied to assess the correlation between ALI and overall/recurrence-free/progression-free survival (OS/PFS/RFS) in LC. Results. A total of 1587 LC patients from eight articles were recruited. Pooled results indicated that pretreatment ALI was significantly associated with prognosis in cases with LC. Compared to those with high-ALI, LC cases in the low-ALI group had a poorer OS (HR: 1.64, 95% CI: 1.34-1.93, p<0.001). Subgroup analyses further revealed the negative significant prognostic value of low ALI in LC. In addition, low ALI had obvious connection with inferior PFS/RFS (HR: 1.71, 95% CI: 1.35-2.07, p<0.001) in LC patients. Conclusions. Low ALI before treatments indicates poor prognosis in LC patients. Serum ALI may serve as a promising predictive tumor marker of survival in LC sufferers.


Sign in / Sign up

Export Citation Format

Share Document